NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IBIO

iBio Inc

Jun 30 • 04:00PM ET

0.7631

Dollar change +0.0081
Percentage change 1.07	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX ARCT INO CODX OCGN VXRT ADMA IBRX ALT APRE

| Held by: VXF VTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.33	Insider Own	5.67%	Shs Outstand	16.22M	Perf Week	7.12%
Market Cap	12.38M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	35.46%	Shs Float	15.30M	Perf Month	-2.37%
Enterprise Value	11.29M	PEG	-	EPS next Q	-0.34	Inst Own	15.95%	Short Float	5.41%	Perf Quarter	-81.48%
Income	-20.99M	P/S	32.58	EPS this Y	56.08%	Inst Trans	-0.94%	Short Ratio	0.31	Perf Half Y	-68.41%
Sales	0.38M	P/B	0.67	EPS next Y	53.67%	ROA	-47.53%	Short Interest	0.83M	Perf YTD	-68.85%
Book/sh	1.13	P/C	2.50	EPS next 5Y	-	ROE	-90.83%	52W High	6.89 -88.93%	Perf Year	-63.14%
Cash/sh	0.31	P/FCF	-	EPS past 3/5Y	52.32% 57.55%	ROIC	-153.16%	52W Low	0.64 20.02%	Perf 3Y	-99.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-54.39% -35.52%	Gross Margin	-199.20%	Volatility	17.00% 13.43%	Perf 5Y	-99.89%
Dividend TTM	-	EV/Sales	29.71	EPS Y/Y TTM	85.42%	Oper. Margin	-4483.47%	ATR (14)	0.12	Perf 10Y	-99.99%
Dividend Ex-Date	-	Quick Ratio	1.12	Sales Y/Y TTM	650.00%	Profit Margin	-5597.87%	RSI (14)	41.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.12	EPS Q/Q	42.30%	SMA20	-10.87%	Beta	0.94	Target Price	4.87
Payout	-	Debt/Eq	0.34	Sales Q/Q	-	SMA50	-10.39%	Rel Volume	0.49	Prev Close	0.75
Employees	19	LT Debt/Eq	0.20	Earnings	May 02 BMO	SMA200	-68.97%	Avg Volume	2.65M	Price	0.76
IPO	Aug 19, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	-53.12% -100.00%	Trades		Volume	1,327,104	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-24	Initiated	Chardan Capital Markets	Buy	$5
Nov-29-21	Initiated	JMP Securities	Mkt Outperform	$1.50
Jan-22-21	Initiated	Cantor Fitzgerald	Overweight	$3
Jun-26-20	Initiated	Alliance Global Partners	Buy	$2.55

Jun-24-25 07:00AM	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results (GlobeNewswire)
Jun-23-25 04:15PM	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call (GlobeNewswire) -7.60%
Jun-16-25 07:00AM	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment (GlobeNewswire) -5.83%
May-05-25 08:00AM	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model (GlobeNewswire)
May-02-25 08:00AM	iBio Reports Fiscal Third Quarter 2025 Financial Results (GlobeNewswire)
01:43PM	Loading…
Apr-29-25 01:43PM	iBio Raises $6.2 Million Through Warrant Inducement Transaction (GlobeNewswire)
Apr-22-25 08:00AM	iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio (GlobeNewswire) -17.43%
Apr-07-25 07:00AM	iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline (GlobeNewswire) -53.18%
Apr-01-25 10:00AM	iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025 (Insider Monkey)
Feb-19-25 04:05PM	iBio to Begin Trading on the Nasdaq Stock Exchange (GlobeNewswire) -5.71%
Feb-17-25 04:38PM	Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:05PM	iBio Reports Fiscal Second Quarter 2025 Financial Results (GlobeNewswire) -8.06% -7.31%
Jan-13-25 07:00AM	iBio Announces New Investments from Board Members and Officers (GlobeNewswire)
Jan-07-25 07:00AM	iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio (GlobeNewswire) +10.16%
Jan-03-25 07:58AM	iBio Expands Pipeline with New Antibody Agreement (TipRanks)
09:24AM	Loading…
Jan-02-25 09:24AM	Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform (Benzinga)
07:00AM	iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio (GlobeNewswire)
Nov-25-24 08:00AM	iBio Strengthens Board with Appointment of Two New Independent Directors (GlobeNewswire)
Nov-12-24 04:05PM	iBio Reports Fiscal First Quarter 2025 Financial Results (GlobeNewswire) -9.02%
Oct-10-24 08:00AM	iBio and AstralBio Provide Update on Myostatin Program for Obesity (GlobeNewswire) -7.75%
Sep-20-24 04:05PM	iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -6.09%
Sep-03-24 07:00AM	iBio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 04:30PM	iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development (GlobeNewswire) +23.42%
Jun-03-24 07:00AM	iBio Closes Sale of Manufacturing Facility in Texas (GlobeNewswire)
May-13-24 04:05PM	iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-05-24 02:35PM	3 Healthcare Stocks Short Sellers Are Prescribing for Trouble (InvestorPlace) -15.26%
Mar-27-24 07:00AM	iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases (GlobeNewswire) +192.17%
Mar-26-24 07:35PM	iBio Announces $15.0 Million Private Placement (GlobeNewswire) +5.02%
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-26-24 07:45AM	iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka (GlobeNewswire)
08:15AM	Loading…
Jan-16-24 08:15AM	iBio Announces Participation in 23rd Annual PepTalk Conference (GlobeNewswire)
Dec-26-23 07:15AM	iBio Amends and Extends Maturity of Credit Agreement (GlobeNewswire)
Dec-05-23 08:00AM	iBio, Inc. Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -50.00%
Nov-27-23 05:20PM	iBio Announces Reverse Stock Split (GlobeNewswire) -31.03%
Nov-01-23 08:24AM	iBio Further Expands Tech Stack with ShieldTx; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific (GlobeNewswire)
Oct-10-23 08:00AM	iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics (GlobeNewswire) +7.14%
Oct-02-23 06:45AM	iBio Explains Recent Filing of Registration Statement (GlobeNewswire)
Sep-27-23 04:19PM	iBio Announces Filing of 2023 Annual Report on SEC Form 10-K (GlobeNewswire)
Sep-21-23 04:05PM	iBio Announces Amendment to Credit Agreement with Woodforest (GlobeNewswire)
Aug-14-23 04:15PM	iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development (GlobeNewswire) -6.53%
Jun-27-23 08:00AM	iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Companys Next Stage of Growth (GlobeNewswire) -7.38%
Jun-20-23 08:25AM	3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever (InvestorPlace)
Jun-12-23 04:15PM	iBio Forges Research Collaboration with the National Institutes of Health (GlobeNewswire)
Jun-06-23 08:00AM	iBio Expands Tech Stack with EngageTx; Adds TROP-2 Bispecific to Development Pipeline (GlobeNewswire) +9.25%
May-09-23 04:30PM	iBio to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
Apr-04-23 04:05PM	iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform (GlobeNewswire) -12.35% -18.12%
Mar-31-23 08:10AM	iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing (GlobeNewswire)
Feb-16-23 04:48PM	iBio Announces MUC16 as its Latest Immune-Oncology Target Program (GlobeNewswire) -11.86% +97.28%
Jan-05-23 08:00AM	iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine (GlobeNewswire) -5.23%
Dec-09-22 04:05PM	iBio Announces Closing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -7.16%
Dec-06-22 11:27PM	iBio Announces Pricing of $3.5 Million Underwritten Public Offering (GlobeNewswire) -57.88%
04:01PM	iBio Announces Proposed Underwritten Public Offering (GlobeNewswire)
08:00AM	iBio to Participate in the JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Dec-05-22 08:00AM	iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022 (GlobeNewswire)
Dec-02-22 04:30PM	iBio Announces CEO Departure (GlobeNewswire) +6.25%
Nov-03-22 08:00AM	iBio Accelerates Transformation to AI-Powered Biotech (GlobeNewswire) -9.71%
Oct-27-22 06:40PM	7 Penny Stocks to Sell Pronto Before a Painful Downturn (InvestorPlace) -5.14%
Sep-30-22 11:48AM	3 Healthcare Stocks to Sell Before They Die (InvestorPlace) -6.53%
Sep-27-22 04:30PM	Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents) -32.28%
04:10PM	iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 08:30AM	iBio Acquires RubrYc Therapeutics AI Drug Discovery Platform and Pipeline (GlobeNewswire) +12.18%
Aug-16-22 09:00AM	iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate (GlobeNewswire)
May-18-22 08:00AM	iBio to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.55%
May-16-22 10:25AM	iBio (IBIO) Q3 2022 Earnings Call Transcript (Motley Fool)
May-12-22 04:05PM	iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +10.12% -7.00%
May-09-22 08:00AM	iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer (GlobeNewswire)
May-05-22 04:30PM	iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022 (GlobeNewswire) -8.38%
May-02-22 08:00AM	iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants (GlobeNewswire)
Mar-11-22 08:00AM	iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-14-22 04:05PM	iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-07-22 04:30PM	iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022 (GlobeNewswire)
Jan-26-22 11:21AM	iBio Advances Its Vaccine Program for Multi-Variant COVID-19 Disease (Benzinga)
09:00AM	iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease (GlobeNewswire)
Jan-04-22 04:30PM	iBio Announces Participation in the H.C. Wainwright BioConnect Conference (GlobeNewswire) -6.78%
Dec-22-21 09:25AM	iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 (GlobeNewswire)
Dec-21-21 09:20AM	iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting (GlobeNewswire)
Dec-10-21 08:30AM	iBio Announces Partial Adjournment of Annual Meeting to December 22 (GlobeNewswire)
Nov-30-21 11:57AM	10 Biotech Penny Stocks to Buy Now (Insider Monkey) -12.73%
08:00AM	ISS Joins Glass Lewis in Recommending Shareholders Vote FOR All Proposals Ahead of iBios Upcoming Annual Meeting (GlobeNewswire)
Nov-29-21 08:45AM	Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202 (GlobeNewswire) +29.15%
Nov-17-21 04:30PM	Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote FOR All Proposals Ahead of Annual Meeting (GlobeNewswire) -6.08%
Nov-15-21 04:05PM	iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.97%
01:00PM	iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors (GlobeNewswire)
Nov-08-21 04:30PM	iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021 (GlobeNewswire)
Nov-03-21 04:47PM	iBio Acquires FastPharming Manufacturing Facility® (GlobeNewswire) +9.08%
Oct-26-21 08:35AM	iBio Urges Shareholders to Vote FOR All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9 (GlobeNewswire)
Oct-02-21 07:31AM	This Under-the-Radar Pharma Company Could Be a Bargain Hunter's Dream (Motley Fool)
Sep-27-21 07:30AM	iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-20-21 04:30PM	iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference (GlobeNewswire) -7.32%
07:30AM	iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021 (GlobeNewswire)
Sep-07-21 04:30PM	iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-26-21 07:00AM	iBio Appoints William D. Clark to its Board of Directors (GlobeNewswire)
Aug-25-21 11:16AM	iBio Expands Immuno-Oncology Pipeline With RubrYc Deal (Benzinga)
07:30AM	iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics (GlobeNewswire)
Jul-15-21 05:10PM	iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate (GlobeNewswire)
Jul-09-21 06:10AM	IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs (Benzinga)
Jul-08-21 04:15PM	iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs (GlobeNewswire)
Jun-18-21 09:13PM	Is IBIO Stock A Buy Here? (Insider Monkey)
Jun-09-21 04:30PM	iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink (GlobeNewswire) +6.04%
May-19-21 04:30PM	iBio to Present at the UBS Global Healthcare Virtual Conference (GlobeNewswire)

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duran Felipe	Chief Financial Officer	Jan 10 '25	Buy	2.72	9,191	25,000	11,139	Jan 13 04:34 PM
Brenner Martin	See Remarks	Jan 10 '25	Buy	2.72	9,191	25,000	18,316	Jan 13 04:34 PM
Banjak Marc	Chief Legal Officer	Jan 10 '25	Buy	2.72	9,191	25,000	11,066	Jan 13 04:33 PM
Arkowitz David	Director	Jan 10 '25	Buy	2.72	18,382	49,999	18,382	Jan 13 04:32 PM
Clark William D	Director	Jan 10 '25	Buy	2.72	1,838	4,999	1,838	Jan 13 04:31 PM
Parada Antonio Bernardino Guim	Director	Jan 10 '25	Buy	2.72	183,823	499,999	183,823	Jan 13 04:30 PM
Sender Gary	Director	Jan 10 '25	Buy	2.72	9,191	25,000	9,191	Jan 13 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBIO

iBio Inc

Upgrade your FINVIZ experience